Citadel Advisors’s Direxion Daily S&P Biotech Bear 3X ETF LABD Stock Holding History

Citadel Advisors’s Portfolio LABD Stock Details LABD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.5M	Sell	91,781 -43,998	-32%	-$833K	﹤0.01%	6715
2025 Q4	$2.86M	Buy	+135,779	New	+$3.68M	﹤0.01%	5261
2025 Q3	–	Sell	-21,207	Closed	-$1.23M	–	13506
2025 Q2	$1.59M	Buy	21,207 +18,261	+620%	+$1.61M	﹤0.01%	6161
2025 Q1	$278K	Buy	+2,946	New	+$216K	﹤0.01%	9769
2024 Q4	–	Sell	-94,952	Closed	-$5.81M	–	14983
2024 Q3	$5.55M	Buy	+94,952	New	+$5.77M	﹤0.01%	3778
2024 Q2	–	Sell	-5,107	Closed	-$431K	–	14922
2024 Q1	$372K	Sell	5,107 -9,009	-64%	-$752K	﹤0.01%	9002
2023 Q4	$1.37M	Buy	14,116 +8,152	+137%	+$1.59M	﹤0.01%	6058
2023 Q3	$1.23M	Buy	5,964 +2,007	+51%	+$326K	﹤0.01%	6153
2023 Q2	$569K	Sell	3,957 -2,078	-34%	-$310K	﹤0.01%	7666
2023 Q1	$1.24M	Sell	6,035 -3,274	-35%	-$556K	﹤0.01%	6315
2022 Q4	$1.61M	Buy	9,309 +2,835	+44%	+$581K	﹤0.01%	5891
2022 Q3	$1.55M	Sell	6,474 -3,236	-33%	-$752K	﹤0.01%	6089
2022 Q2	$3.78M	Buy	9,710 +673	+7%	+$337K	﹤0.01%	4324
2022 Q1	$3.17M	Sell	9,037 -3,721	-29%	-$1.46M	﹤0.01%	5052
2021 Q4	$3.28M	Buy	12,758 +3,045	+31%	+$700K	﹤0.01%	5158
2021 Q3	$2.07M	Buy	9,713 +4,208	+76%	+$895K	﹤0.01%	6265
2021 Q2	$1.06M	Sell	5,505 -11,723	-68%	-$2.63M	﹤0.01%	8217
2021 Q1	$3.75M	Buy	17,228 +16,413	+2,014%	+$3.18M	﹤0.01%	4920
2020 Q4	$206K	Sell	815 -2,823	-78%	-$1.08M	﹤0.01%	9693
2020 Q3	$2.17M	Buy	3,638 +3,285	+931%	+$2.12M	﹤0.01%	4566
2020 Q2	$245K	Buy	353 +85	+32%	+$107K	﹤0.01%	8241
2020 Q1	$754K	Buy	+268	New	+$765K	﹤0.01%	5806
2019 Q3	–	Sell	-157	Closed	-$646K	–	9507
2019 Q2	$566K	Sell	157 -56	-26%	-$236K	﹤0.01%	6627
2019 Q1	$783K	Sell	213 -43	-17%	-$208K	﹤0.01%	6024
2018 Q4	$2.19M	Sell	256 -191	-43%	-$1.4M	﹤0.01%	4005
2018 Q3	$2.18M	Buy	447 +317	+244%	+$1.53M	﹤0.01%	4257
2018 Q2	$671K	Buy	130 +59	+83%	+$358K	﹤0.01%	5890
2018 Q1	$517K	Buy	71 +57	+407%	+$396K	﹤0.01%	5829
2017 Q4	$130K	Buy	+14	New	+$139K	﹤0.01%	7328
2017 Q3	–	Sell	-27	Closed	-$326K	–	7790
2017 Q2	$368K	Sell	27 -29	-52%	-$557K	﹤0.01%	5569
2017 Q1	$1.17M	Buy	+56	New	+$1.38M	﹤0.01%	3784
2016 Q4	–	Sell	-10	Closed	-$356K	–	7582
2016 Q3	$356K	Buy	+10	New	+$468K	﹤0.01%	5382
2016 Q1	–	Sell	-3	Closed	-$184K	–	7407
2015 Q4	$184K	Buy	+3	New	+$229K	﹤0.01%	5913

Other funds holding LABD

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

CCM

Capstone Capital Management Hong Kong $224M AUM

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Cantor Fitzgerald New York $6.78B AUM 29.01% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Citadel Advisors's LABD Position: Q1 2026 in Review

Citadel Advisors reduced its Direxion Daily S&P Biotech Bear 3X ETF (LABD) stake by 32% in Q1 2026, selling an estimated $833K and leaving 91,781 shares worth $1.5M. The position accounts for ﹤0.01% of the portfolio, ranked #6715.

Citadel Advisors first reported a position in LABD in Q4 2015 and has held it in 33 quarters since. The position peaked at $5.55M in Q3 2024. 17 funds tracked by Wall St. Rank hold LABD as of Q1 2026.

Citadel Advisors held 91,781 shares of Direxion Daily S&P Biotech Bear 3X ETF worth $1.5M as of Q1 2026.
Citadel Advisors sold 43,998 Direxion Daily S&P Biotech Bear 3X ETF shares in Q1 2026, an estimated $833K.
Direxion Daily S&P Biotech Bear 3X ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #6715 holding.
Citadel Advisors first reported a position in Direxion Daily S&P Biotech Bear 3X ETF in Q4 2015 and has held it in 33 quarters since.
Citadel Advisors's Direxion Daily S&P Biotech Bear 3X ETF position peaked at $5.55M in Q3 2024.
17 funds tracked by Wall St. Rank held Direxion Daily S&P Biotech Bear 3X ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.